Others

Aurobindo Pharma Ltd. - USFDA Classifies The Inspection Of AurobindoS API/ Intermediates Facilities Of Unit I, IX And XI As OAI

| Updated on May 17, 2019 Published on May 17, 2019

This is to inform that the Company has received letters from the USFDA classifying the inspections concluded at our API facilities of Unit I and XI and intermediates facility of unit IX in February 2019 as Official Action Indicated (OAI).

The Company has already submitted its initial response to USFDA. The Company is sending further updates on the committed corrective actions.

The Company is confident that these OAI classifications will not have an impact on disruption of supplies or the revenue from operations of these facilities.

Please take the information on record.

Pdf Link: Aurobindo Pharma Ltd. - USFDA Classifies The Inspection Of AurobindoS API/ Intermediates Facilities Of Unit I, IX And XI As OAI

Source : BSE - www.bseindia.com

Published on May 17, 2019
This article is closed for comments.
Please Email the Editor